-transparent.png){kind=logo}
The occurrence of pulmonary disease associated with long-term BCNU therapy is reported in two patients treated for astrocytoma grade II whose clinical presentations of pulmonary complications and corresponding tissue alterations showed striking differences. One patient presented with a dramatic, fulminating, and rapidly fatal pulmonary disease. His lungs revealed atypical proliferation of pneumocytes, moderate interstitial inflammation, fibrosis and intra-alveolar hyalin membranes. The second patient presented with slowly progressive dyspnea, ultimately leading to death secondary to severe diffuse alveolar septal fibrosis. Individual differences in response to toxicity are suggested and discussed.
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
March 1969,
The Journal of pharmacology and experimental therapeutics,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
December 1980,
Neurosurgery,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
July 1978,
Cancer,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
June 1995,
Mutation research,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
March 1980,
Cancer,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
August 1981,
Cancer,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
May 1983,
Neurosurgery,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
September 1974,
Biochemical and biophysical research communications,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
January 1992,
Cancer immunology, immunotherapy : CII,
S M Mitsudo, and
E S Greenwald, and
B Banerji, and
L G Koss
August 1971,
The New England journal of medicine,
